Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 28;13(3):e0082422.
doi: 10.1128/mbio.00824-22. Epub 2022 May 16.

Monoclonal Antibodies and Flaviviruses: a Possible Option?

Nicasio Mancini  1
Affiliations
Comment

Monoclonal Antibodies and Flaviviruses: a Possible Option?

Nicasio Mancini. mBio. .

Abstract

M. P. Doyle, J. R. Genualdi, A. L. Bailey, N. Kose, et al. (mBio 13:e00512-22, 2022, https://doi.org/10.1128/mBio.00512-22), report on the cloning of a panel of fully human monoclonal antibodies (mAbs) directed against yellow fever virus (YFV). In particular, mAb YFV-136 is endowed with interesting cross-YFV substrain-neutralizing features. The importance of YFV-136 and other mAbs with similar characteristics is related not necessarily only to their possible future use in the clinic but also to their role in a better understanding of the biology of YFV (as well as of other flaviviruses) for the development of effective therapeutic and prophylactic strategies. The emergence and reemergence of different flaviviruses worldwide in the last decades certainly make this a compelling clinical priority.

Keywords: flaviviruses; monoclonal antibodies; yellow fever virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Comment on

References

    1. Gaythorpe KAM, Hamlet A, Jean K, Ramos DG, Cibrelus L, Garske T, Ferguson N. 2021. The global burden of yellow fever. Elife 10:e64670. doi:10.7554/eLife.64670. - DOI - PMC - PubMed
    1. Bifani AM, Ong EZ, de Alwis R. 2020. Vaccination and therapeutics: responding to the changing epidemiology of yellow fever. Curr Treat Options Infect Dis 12:349–360. doi:10.1007/s40506-020-00232-7. - DOI - PMC - PubMed
    1. Doyle MP, Genualdi JR, Bailey AL, Kose N, Gainza C, Rodriguez J, Reeder KM, Nelson CA, Jethva PN, Sutton RE, Bombardi RG, Gross ML, Julander JG, Fremont DH, Diamond MS, Crowe JE, Jr.. 2022. Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus. mBio 13:e00512-22. doi:10.1128/mbio.00512-22. - DOI - PMC - PubMed
    1. Low JG, Ng JHJ, Ong EZ, Kalimuddin S, Wijaya L, Chan YFZ, Ng DHL, Tan H-C, Baglody A, Chionh Y-H, Lee DCP, Budigi Y, Sasisekharan R, Ooi E-E. 2020. Phase 1 trial of a therapeutic anti-yellow fever virus human antibody. N Engl J Med 383:452–459. doi:10.1056/NEJMoa2000226. - DOI - PubMed
    1. Slon Campos JL, Mongkolsapaya J, Screaton GR. 2018. The immune response against flaviviruses. Nat Immunol 19:1189–1198. doi:10.1038/s41590-018-0210-3. - DOI - PubMed

LinkOut - more resources